https://www.selleckchem.com/pr....oducts/nf-kb-activat
Background The optimal induction treatment in potentially-resectable stage IIIA-N2 NSCLC remains undefined. Aim To compare neoadjuvant high-dose chemoradiotherapy (CRT) to neoadjuvant chemotherapy (CHT) in patients with resectable, stage IIIA-N2 non-small-cell lung cancer (NSCLC). Methods Retrospective, multicentre study of 99 patients diagnosed with stage cT1-T3N2M0 NSCLC who underwent neoadjuvant treatment (high-dose CRT or CHT) followed by surgery between January 2005 and December 2014. Results 47 patients (47.5%) underwent
Aimer
Commentaire
Partagez
